Triple-negative breast cancer trials in Australia

In Australia 31 Also abroad 425

31 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Blacktown, Frankston
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Where
Camperdown, Clayton, North Ryde, Westmead
Age
18 years and over
People
2,400 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00
Phase 1/2Taking people
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Where
Melbourne, Murdoch
Age
18 years and over
People
1,132 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00
Phase 3Taking people
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Where
Brisbane, Frankston, Macquarie University, Westmead
Age
18 years and over
People
1,530 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00
Phase 3Taking people
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Where
Adelaide, Bendigo, Cairns, Campbelltown, Clayton, Darlinghurst, Douglass, Gateshead, Murdoch, Port Macquarie, Woolloongabba
Age
18 years and over
People
1,514 worldwide
Run by
Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00
Phase 1Taking people
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Where
Adelaide, QLD
Age
18 years and over
People
575 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Darlinghurst, Nedlands
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Early phase 1Taking people
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Where
Adelaide, Gosford, Kingswood, Murdoch, Southport, Wollongong
Age
18 years and over
People
30
Run by
Radiopharm Theranostics, Ltd
See details and how to joinNCT06305962
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Adelaide, Darlinghurst, Frankston, Melbourne, Westmead
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 1/2Taking people
Intratumoral N17350 in Advanced Solid Tumors
Where
Melbourne, Newcastle, Westmead
Age
18 years and over
People
275 worldwide
Run by
Onchilles Pharma Inc
See details and how to joinNCT07339176
Phase 1Taking people
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Where
Camperdown, Heidelberg
Age
18 years and over
People
325 worldwide
Run by
AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00
Early phase 1Taking people
Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
Where
Nedlands, Perth, St Leonards
Age
18 years and over
People
40 worldwide
Run by
RayzeBio, Inc.
See details and how to joinNCT07671092
Phase 1Taking people
A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors
Where
Darlinghurst
Age
18 years and over
People
66 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07801508
Phase 1/2Taking people
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Where
East Melbourne
Age
18 years and over
People
120 worldwide
Run by
AstraZeneca
See details and how to joinNCT07115043
Phase 1Taking people
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Where
Gold Coast, Heidelberg, Newcastle, Perth, Wahroonga, Westmead
Age
18 years and over
People
162
Run by
Context Therapeutics Inc.
See details and how to joinNCT07545122
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Bedford Park, Camperdown, Clayton, Nedlands, South Brisbane
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1/2Taking people
Study of AVZO-021 in Patients With Advanced Solid Tumors
Where
Macquarie University, Wollongong
Age
18 years and over
People
430 worldwide
Run by
Avenzo Therapeutics, Inc.
See details and how to joinNCT05867251
Phase 3Taking people
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Where
Camperdown, Darlinghurst, Heidelberg, Melbourne, Nedlands, Waratah
Age
18 years and over
People
625 worldwide
Run by
AstraZeneca
See details and how to joinNCT06103864
Phase 1Taking people
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Where
Adelaide, Brisbane, Camperdown, Geelong, Sydney
Age
18 years and over
People
76 worldwide
Run by
Kivu Bioscience Inc.
See details and how to joinNCT07229313
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Liverpool, Melbourne, Subiaco, Woolloongabba
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
Phase 1Taking people
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
Where
Southport, Waratah
Age
18 years to 75 years
People
299 worldwide
Run by
Huahui Health
See details and how to joinNCT07623369
Phase 1/2Taking people
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Where
Blacktown, Brisbane, Liverpool, Malvern, Melbourne, Nedlands
Age
18 years and over
People
1,109 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT04895709
Phase 1Not yet taking people in Australia
A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors.
Where
Nedlands
Age
18 years and over
People
16
Run by
Radiopharm Theranostics, Ltd
See details and how to joinNCT07272642
Phase 1/2Taking people
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Where
Melbourne, Sydney
Age
18 years and over
People
270 worldwide
Run by
Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00
Phase 2/3Taking people
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Where
Ballarat Central, Brisbane, Heidelberg, Macquarie University, Melbourne, Subiaco
Age
18 years and over
People
600 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00